GlobalData on MSN
Neurocrine Biosciences begins phase II NBI-1065890 trial for TD
The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results